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In making the case for considering quality-of-life out-
comes in the treatment of addiction (Addiction Science
& Clinical Practice, July 2011 [1]), Dr. Alexandre Laudet
argues that “reduced substance abuse is not in itself an
adequate criterion for recovery [p. 49].” In this respect,
however, management of drug dependence is no differ-
ent than the almost universal approach to assessing care
of all other chronic medical conditions. For example, in
treating patients with diabetes or hypertension, the over-
whelming (usually exclusive) focus is on the mainte-
nance of blood sugar and blood pressure levels; in the
treatment of epilepsy, efficacy is a function of the elimi-
nation or reduction in frequency of seizures. It is diffi-
cult to argue with Dr. Laudet’s view that it would be
appropriate and useful to ask substance abuse patients,
“Overall, how satisfied are you with your life?”, but how
often is this question posed by clinicians treating other
chronic medical ailments?
Paradoxically, providers of substance abuse treatment
demonstrate both too much and too little focus on
quality-of-life parameters. Thus, with regard to medica-
tion-assisted treatment, most programs set criteria for
“termination” based on attendance, adherence to coun-
seling schedules, and urine toxicology results, and they
apply these criteria rigidly, with no regard whatsoever as
to how favorably the patient judges her or his improved
overall condition. Other programs, however, make
demands on patients that far transcend the primary pro-
blem they treat–drug dependence–and in some cases
even discharge patients who fail to find employment
within a specified period of time, even when illicit drug
use has ceased altogether [2].
The best approach would seem to be to apply to
addiction treatment precisely the same perspectives and
practices, good and bad, as are commonplace in the
care of all other chronic ailments.
Author Reply
Dr. Newman raises interesting points that are frequently
mentioned when quality of life is discussed in the con-
text of substance use disorders (SUDs). Thank you for
the opportunity to offer some clarifications.
Pointing out that the nearly exclusive focus of treat-
ment for other chronic conditions– e.g., asthma–is on
reducing and managing symptoms, Dr. Newman writes,
“The best approach would seem to be to apply to
addiction treatment precisely the same perspectives and
practices, good and bad, as are commonplace in the
care of all other chronic ailments.” From the perspective
of specialty care (i.e., addiction treatment), especially
medication-assisted treatment, it may seem difficult to
disagree: Clients are diagnosed with a physical condition
and prescribed the most effective pharmacotherapy for
their diagnosis.a
However, this loses sight of the fact that SUDs are
somewhat unique among chronic conditions in that, for
many, they typically present with numerous co-occurring
functional impairments (physical- and mental-health pro-
blems, of course, but also housing instability, damaged
family and social relations, and poor job readiness or
employability). These domains are what constitute “qual-
ity of life.” As argued in my article, improvement in these
impaired areas of functioning are desirable and, some
would argue, necessary, for reductions in or cessation of
substance misuse to be optimized and sustained.
The suggestion that we ask patients, “Overall, how satis-
fied are you with your life?” clearly requires scientific
investigation to determine the most effective way to
obtain a preliminary sense of a patient’s overall quality of
functioning. Note that, in the primary-care setting,
although doctors may not inquire about quality of life per
se, they often ask about stress level and/or major changes
or difficulties in the patient’s life that might better inform
care.
In closing, some misconceptions that often fuel objec-
tions to considering quality of life in the context of SUD
treatment should be addressed. First, the argument
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implies that clinicians be held accountable for making
clients “happy.” This is a gross oversimplification. Clini-
cians in any field are accountable, first and foremost, for
facilitating symptom reduction. However, because of the
high prevalence of co-occurring functional impairments
among SUD patients, and of the emerging evidence
that functional improvements prospectively enhance
motivation for, and the likelihood of, sustained absti-
nence, providing SUD-affected persons with the tools
and resources to improve functioning is highly desirable.
In the current service-delivery system, this may take the
form of referrals to vocational or housing services when
such services are not integrated in the treating agency.
Second, as discussed in the article, the full relevance
of considering quality of life in the treatment of addic-
tion is in the context of recovery-oriented systems of
care (ROSC), whose central goal is to promote not just
symptom reduction but recovery (defined as abstinence
and improvements in functioning). The intensive, time-
limited specialty-care treatment model is well-suited to
initiate remission (symptom reduction), but it is not
sufficient to, nor was it designed to, promote recovery
as currently conceptualized. Recovery is a multifaceted
process that unfolds over time and goes well beyond
symptom reduction. For many, it requires far more than
a brief episode of professionally delivered SUD treat-
ment, as evidenced by the increasing body of science
supporting the usefulness of post-treatment services and
of adopting a recovery orientation to address SUD.
Alexandre B. Laudet, PhD
Center for the Study of Addictions and Recovery,
National Development and Research Institutes, Inc.,
New York, NY, USA.
Email: Alexandre B. Laudet - laudet@ndri.org
Endnote
aEditor’s note: Quality of life is relevant to pharma-
cotherapies in that the Food and Drug Administration
requires evidence of patient reported outcomes, includ-
ing quality of life, to support labeling claims [3].
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